Biotechnology APIs & Biosimilars
Provider 
Founded 1972
Sells To Consumers, Hospitals
Pricing Model Product Sales
Ownership Private

Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.
Cristália's biotechnology unit operates plants certified by Anvisa under current good biological practices since 2013 and 2014, making it the first Brazilian pharmaceutical company with CBPF certification for biological active ingredients. It produces fully national somatropin and animal-free collagenase using bacterial and animal-cell platforms.
The unit developed the first biotechnology active ingredient derived from Brazilian biodiversity and holds Anvisa approval for biosimilar production.
Biocon

Biocon — Biosimilars Portfolio
biocon.com
Bionovis

Bionovis — Biologic and Biosimilar Medicines
bionovis.com.br
Fresenius Kabi

Fresenius Kabi Brasil Biopharma
fresenius-kabi.com
Samsung Bioepis
Samsung Bioepis — Biosimilars Portfolio
samsungbioepis.com
| Attribute | Biotechnology APIs & Biosimilars | Biocon — Biosimilars Portfolio | Bionovis — Biologic and Biosimilar Medicines | Fresenius Kabi Brasil Biopharma | Samsung Bioepis — Biosimilars Portfolio | |
|---|---|---|---|---|---|---|
| Provider | ||||||
| Founded | 1972 | 1978 | 2012 | — | 2012 | |
| Sells To | Consumers, Hospitals | Enterprise, Government | — | — | — | |
| Pricing Model | Product Sales | Recurring, Software, Transactional | — | — | — | |
| Ownership | Private | Public | — | — | — |
Provider 
Founded 1972
Sells To Consumers, Hospitals
Pricing Model Product Sales
Ownership Private
Provider 
Founded 1978
Sells To Enterprise, Government
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider 
Founded 2012
Sells To —
Pricing Model —
Ownership —
Provider 
Founded —
Sells To —
Pricing Model —
Ownership —
Provider Samsung Bioepissamsungbioepis.com
Founded 2012
Sells To —
Pricing Model —
Ownership —
Blau Farmacêutica's active-pharmaceutical-ingredient (IFA) production, including a dedicated high-complexity biotech raw-materials plant.


Microbiológica's GMP synthetic active-pharmaceutical-ingredient line for human use, produced via validated synthetic procedures.


Bionovis Biotec operates industrial mammalian-cell biomanufacturing lines in Brazil.


Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.


EMS's hospital unit supplying medicines and solutions to hospitals and institutional healthcare buyers, reinforced by a 2026 injectables acquisition.


Oncology portfolio of chemotherapies and targeted therapies described as Brazil's largest chemotherapy offering.
Blau Farmacêutica's active-pharmaceutical-ingredient (IFA) production, including a dedicated high-complexity biotech raw-materials plant.
Microbiológica's GMP synthetic active-pharmaceutical-ingredient line for human use, produced via validated synthetic procedures.

Bionovis Biotec operates industrial mammalian-cell biomanufacturing lines in Brazil.

Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.

EMS's hospital unit supplying medicines and solutions to hospitals and institutional healthcare buyers, reinforced by a 2026 injectables acquisition.

Oncology portfolio of chemotherapies and targeted therapies described as Brazil's largest chemotherapy offering.

Truxima is a rituximab biosimilar medicine used in blood cancer and autoimmune care.
